LOGIN  |  REGISTER
Viking Therapeutics
Cue Biopharma

RadNet to Present at the 43rd Annual Cowen & Company Healthcare Conference on Tuesday, March 7th

March 06, 2023 | Last Trade: US$72.70 1.32 1.85

LOS ANGELES, March 06, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer and Gregory Sorensen, M.D., CEO and co-founder of DeepHealth (RadNet’s Artificial Intelligence Division), will be presenting at the Cowen & Company Healthcare Conference on Tuesday, March 7, 2023 at 9:50 a.m. Eastern Time (6:50 a.m. Pacific Time).

There will be simultaneous and archived webcasts available at https://wsw.com/webcast/cowen132/rdnt/2026416 and www.radnet.com under the “About RadNet'' menu section and “News and Press Releases'' sub-menu of the website.

Details for RadNet's Presentation:
Date: Tuesday, March 7, 2023
Time: 9:50 a.m. Eastern Time / 6:50 a.m. Pacific Time
URL: https://wsw.com/webcast/cowen132/rdnt/2026416

About RadNet, Inc.

RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 357 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey and New York. Together with affiliated radiologists, inclusive of full-time and per diem employees and technologists, RadNet has a total of over 9,000 employees. For more information, visit http://www.radnet.com.

Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2928

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB